Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Novartis' Pluvicto is expected to dominate the market for radioligand therapies for prostate cancer, with ...

Tris Pharma, Inc. (Tris) has announced the promotion of Manesh Naidu, MBA, to chief commercial officer. Naidu previously ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

According to US secondary stroke prevention guidelines, patients with ESUS should not be treated with anticoagulants or ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

This Comment is linked to The Lancet Haematology Series on Sexual Health in Patients with Haematological Malignancies; we ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.

Today, the Lonza Board of Directors announced the nomination of Juan Andres and Eric Drapé as Independent Members of the Board. The Board will propose to shareholders the election of both nominees at ...